å¹æ¹èµæ¬( Med-Fine Capital )ä¸æ³¨äºå»è¯å¥åº·ä¸çå½ç§å¦é¢åæèµãåºé管çå¢éå
·ææ·±åçå»è¯å¥åº·äº§ä¸èæ¯å丰å¯çé£é©æèµç»éªãæ»é¨å¨ä¸æµ·,ä¸å¡éå¸ä¸å½,ç§æ¿âä¸æ³¨å»è¯å¥åº·ä¸çå½ç§å¦,åæ¥èµ...
Investment Type: Venture Capital
Mentions in press and media 2
| Date | Title | Description |
| 22.03.2026 | Excalipoint Therapeutics Secures $68.7M for Next-Gen TCE Therapies | Excalipoint Therapeutics, a dynamic Shanghai-based biotechnology firm, secured $68.7 million in oversubscribed seed funding. This substantial capital propels its mission to redefine T-cell engager (TCE) therapies. The company is tackling si... |
| 18.03.2026 | Excalipoint Therapeutics Raises $68.7M in Seed Funding | Excalipoint Therapeutics, a Shanghai, China-based biotechnology company developing T-cell engager (TCE) therapies for cancer and autoimmune diseases, raised $68.7M in Seed funding. Backers included HSG, Apricot Capital, Yuanbio Venture Capi... |